Claims for Patent: 7,858,070

Summary for Patent: 7,858,070

Title:	Multivalent immunoglobulin-based bioactive assemblies
Abstract:	The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and/or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and/or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and/or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and/or diagnostic agents.
Inventor(s):	Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), Rossi; Edmund A. (Woodland Park, NJ)
Assignee:	IBC Pharmaceuticals, Inc. (Morris Plains, NJ)
Application Number:	12/396,605
Patent Claims:	1. A method of delivering a diagnostic or therapeutic agent comprising: a) obtaining a stably tethered structure comprising at least one diagnostic or therapeutic agent, wherein the stably tethered structure comprises (i) an IgG antibody that binds to tumor-associated antigen wherein the antibody is attached to two AD anchor domain) moieties and (ii) four copies of a cytokine, each cytokine attached to a DDD (dimerization and docking domain) moiety, wherein the AD moiety has the peptide sequence from an anchoring domain of an AKAP (A-kinase anchoring protein) selected from the group consisting of AD1 (SEQ ID NO: 3) and AD2 (SEQ ID NO: 4) and the DDD moiety has the peptide sequence from a dimerization and docking domain of protein kinase A selected from the group consisting of DDD1 (SEQ ID NO: 1) and DDD2 (SEQ ID NO: 2); and b) administering the stably tethered structure to a subject. 2. The method of claim 1, wherein the DDD moieties bind to each other to form dimers and each AD moiety binds to a dimer of DDD moieties. 3. The method of claim 1, wherein the cytokines are selected from the group consisting of G-CSF, interferon-.beta.1A, interferon-.alpha.2b and erythropoietin. 4. The method of claim 1, wherein the a tumor-associated antigen is selected from the group consisting of carbonic anhydrase IX, alpha-fetoprotein, BrE3-antigen, CA125, CD1, CD1a, CD3, CD5, CD15, CD16, CD19, CD20O, CD21, CD22, CD23, CD25, CD30, CD33, CD38, CD45, CD74, CD79a, CD80, CD138, colon-specific antigen-p (CSAp), CEA (CEACAM5), CEACAM6, EGFR, EGP-1, EGP-2, Ep-CAM, Flt-1, Flt-3, folate receptor, G250 antigen, HLA-DR, human chorionic gonadotropin (HCG) and its subunits, HER2/neu, hypoxia inducible factor (HIF-1), Ia, IL-2, IL-6, IL-8, insulin-like growth factor-1 (ILGF-1), ILGF-1 receptor, KC4-antigen, KS-1-antigen, KS1-4, Le-Y, macrophage migration inhibitory factor (MIF), MAGE, MUC1, MUC2, MUC3, MUC4, NCA66, NCA95, NCA90, antigen specific for PAM-4 antibody, placental growth factor, p53, prostatic acid phosphatase, PSA, PSMA, RS5, S100, TAC, TAG-72, tenascin, TRAIL receptors, Tn antigen, Thomson-Friedenreich antigens, tumor necrosis factor-.alpha., tumor necrosis factor-.beta., VEGF, ED-B fibronectin, and 17-1A antigen. 5. The method of claim 1, wherein the therapeutic agent is selected from the group consisting of a chemotherapeutic agent, a cytokine, a chemokine, an anti-angiogenic agent, an apoptotic agent, a drug, a prodrug, a toxin, an enzyme, a radioisotope, an immunomodulator, an antibiotic, an antibody, an antibody fragment and a hormone. 6. The method of claim 1, wherein the IgG antibody is selected from the group consisting of LL1 (anti-CD74), LL2 (anti-CD22), RFB4 (anti-CD22), A20 (anti-CD20), L243 (anti-HLA class II), CC49 (anti-TAG-72), MN-14 (anti-CEA), MN-15 (anti-CEA), 679 (anti-HSG), 734 (anti-In-DTPA), L19 (anti-ED-B fibronectin), R1 (anti-IGF-1R), PAM4 (anti-MUC1), RS7 (anti-EGP-1), adalimumab, infliximab, omalizumab and palivizumab. 7. The method of claim 1, wherein the antibody is a human, humanized or chimeric antibody. 8. The method of claim 1, wherein the diagnostic agent is selected from the group consisting of a radioisotope, an imaging agent, a dye, an enzyme, a fluorescent agent, a chemiluminescent agent, a bioluminescent agent, a paramagnetic ion and an ultrasound label. 9. A method of treating B cell leukemia or B cell lymphoma comprising: a) obtaining a stably tethered structure comprising at least one therapeutic agent, wherein the stably tethered structure comprises (i) an IgG antibody that binds to tumor associated antigen wherein the antibody is attached to two AD moieties and (ii) four copies of a or cytokine, each or cytokine attached to a DDD moiety, wherein the AD moiety has the peptide sequence from an anchoring domain of an AKAP (A-kinase anchoring protein) selected from the group consisting of AD1 (SEQ ID NO: 3) and AD2 (SEQ ID NO: 4) and the DDD moiety has the peptide sequence from a dimerization and docking domain of protein kinase A selected from the group consisting of DDD1 (SEQ ID NO: 1) and DDD2 (SEQ ID NO: 2); and b) administering the stably tethered structure to a subject with cancer. 10. The method of claim 9, wherein the cytokines are selected from the group consisting of G-CSF, interferon-.beta.1A, interferon-.alpha.2b and erythropoietin. 11. The method of claim 9, wherein the tumor-associated antigen is selected from the group consisting of carbonic anhydrase IX, alpha-fetoprotein, BrE3-antigen, CA125, CD1, CD1a, CD3, CD5, CD15, CD16, CD19, CD20, CD21, CD22, CD23, CD25, CD30, CD33, CD38, CD45, CD74, CD79a, CD80, CD138, colon-specific antigen-p (CSAp), CEA (CEACAM5), CEACAM6, EGFR, EGP-1, EGP-2, Ep-CAM, Flt-1, Flt-3, folate receptor, G250 antigen, HLA-DR, human chorionic gonadotropin (HCG) and its subunits, HER2/neu, hypoxia inducible factor (HIF-1), Ia, IL-2, IL-6, IL-8, insulin-like growth factor-1 (ILGF-1), ILGF-1 receptor, KC4-antigen, KS-1-antigen, KS1-4, Le-Y, macrophage migration inhibitory factor (MIF), MAGE, MUC1, MUC2, MUC3, MUC4, NCA66, NCA95, NCA90, antigen specific for PAM-4 antibody, placental growth factor, p53, prostatic acid phosphatase, PSA, PSMA, RS5, S100, TAC, TAG-72, tenascin, TRAIL receptors, Tn antigen, Thomson-Friedenreich antigens, tumor necrosis factor-.alpha., tumor-necrosis factor-.beta., VEGF, ED-B fibronectin, and 17-1A-antigen. 12. The method of claim 11, further comprising administering a chemotherapeutic agent, a cytokine, radiation therapy, immunotherapy, radioimmunotherapy, localized hyperthermia, laser irradiation, an anti-angiogenic agent or surgical excision in combination with the stably tethered structure.

Details for Patent 7,858,070

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2025-10-19
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2025-10-19
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2025-10-19
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2025-10-19
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		2025-10-19
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	03/05/1973		2025-10-19
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2025-10-19